South America’s drug patent landscape isn’t “messy”—it’s strategic. And if you’re treating it like a single market, you’re likely missing the real story: the rules of exclusivity, enforcement, and pipeline protection vary dramatically country by countr…
South American Drug Patents: The Definitive Country-by-Country Breakdown Read Post »
Biopharma’s “Patent Cliff” Isn’t Just a Legal Event—it’s a Commercial Deadline.
If you’re in biopharma commercial, market access, or business development, you already know the headline: patents expire, generics and biosimilars arrive, and pricing press…
Biopharma is entering a new talent cycle—and the “next place” isn’t a lab, a clinic, or even a specific therapeutic area.
It’s the patent landscape.
A recent analysis from DrugPatentWatch on biosimilar patent wars makes a point that should be impossibl…
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »
Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting a deal, or forecasting exclusivity value in Asia-Pacific, here’s the uncomfortable truth: “patent term” is n…
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Most business development teams wait for the “cliff” to arrive—then scramble to win the scramble.
But in biologics, the cliff is predictab…
Generic competition isn’t just a legal event—it’s a business strategy.
For years, the industry narrative has been simple: once a patent expires, generics arrive, prices fall, and the market resets. But the real story—especially in branded pharmaceuti…
Patients aren’t asking “about patents.” They’re asking, “Will I be able to afford my medicine?”
If you’ve spent any time around drug pricing conversations lately, you’ve probably noticed a pattern: the most searched questions online rarely sound like l…
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
In pharma, the phrase patent cliff is often treated like weather: inevitable, disruptive, and largely outside your control. But the most effective companie…
Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before Drug Patent LOE Read Post »
Your drug’s “patent life” isn’t one number in the GCC. It’s a moving target.
If you’re launching (or defending) a branded medicine in the Gulf Cooperation Council, the biggest misconception is simple: patent term is the same everywhere.
In reality, t…
Know Exactly How Long Your Drug Patent Lasts in the GCC Read Post »
Biopharma teams don’t lose deals because they lack ambition. They lose because timing is misaligned.
In licensing, partnering, and BD strategy, the “pitch” is rarely just a pitch. It’s a calendar—built on patent life, regulatory milestones, and the ung…